Search

Displaying results 2511 - 2520 of 8517 in total
  1. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving … This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR

  2. Drug

    Dalteparin

    go.drugbank.com/drugs/DB06779
    ApprovedInvestigational

    Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains ...

  3. Drug

    Palopegteriparatide

    go.drugbank.com/drugs/DB18676
    ApprovedInvestigational

    [L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.

  4. Drug

    Flutemetamol (18F)

    go.drugbank.com/drugs/DB09151
    ApprovedInvestigational

    It is used to evaluate Alzheimer's disease (AD) or other causes of cognitive decline as an Aβ-specific positron emission tomography (PET) ligand.[L35029]

  5. Drug

    Eplerenone

    go.drugbank.com/drugs/DB00700
    ApprovedInvestigational

    Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative

  6. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    It is currently under development as topical treatment of psoriasis. … Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

  7. Drug

    Interferon Gamma

    go.drugbank.com/drugs/DB15753
    Investigational

    It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.

  8. Drug

    Omidubicel

    go.drugbank.com/drugs/DB17132
    ApprovedInvestigational

    It is administered as a single intravenous dose specific to each patient. … Omidubicel is a nicotinamide-modified allogeneic hematopoietic progenitor cell therapy derived from cord blood used as an allogeneic stem cell donor source.

  9. Drug

    Human botulinum neurotoxin A/B immune globulin

    go.drugbank.com/drugs/DB14115
    Approved

    to more serious symptoms such as respiratory arrest and flaccid paralysis. … [L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism.

  10. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.